Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Oral,Sublingual,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bulgaria | Canada | Czech | Denmark | Estonia | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Allergy Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Bulgaria, Czech Republic, Germany, Latvia, Lithuania, Poland, Romania, Slovakia, Spain, United Kingdom
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Asthma, Allergic|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Rhinitis, Allergic, Seasonal
Phase 2: Grass Pollen Hypersensitivity
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PQGrass308 | P3 |
Unknown Status |
Conjunctivitis, Allergic|Rhinitis, Allergic, Seasonal |
2032-10-31 |
|
SC-3C2A | P3 |
Unknown Status |
Conjunctivitis, Allergic|Rhinitis, Allergic|Asthma, Allergic |
2026-09-30 |
|
PM/0059 | P3 |
Unknown Status |
Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Conjunctivitis, Allergic |
2026-08-31 |
|
2023-505880-35-00 | P3 |
Unknown Status |
Rhinitis, Allergic|Conjunctivitis, Allergic|Asthma, Allergic |
2025-10-30 |